LeMaitre Vascular Doubles Its Stock Repurchase Program From $5mm to $10mm
November 09 2011 - 2:40PM
LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of peripheral
vascular devices and implants, today announced that its Board of
Directors has doubled its stock repurchase authorization to an
aggregate of $10mm of its Common Stock, to be purchased from time
to time in the open market or in privately negotiated transactions.
Since the program began in August 2009, $4.2mm of shares have been
repurchased. Repurchases may be made under a Rule 10b5-1
plan, which permit shares to be repurchased when the Company might
otherwise be precluded from doing so under insider trading laws.
The authority for the repurchase program has been extended for two
years until December 31, 2013, unless earlier suspended or
discontinued or unless further extended by the Company's Board of
Directors. The program is funded by the Company's cash and cash
equivalents.
LeMaitre Vascular to Present at Upcoming Investor
Conferences
The Company also announced its participation in several upcoming
conferences.
- The Company will present at the Brean Murray, Carret & Co.
2011 Life Sciences Summit in New York City at the Grand Hyatt New
York Hotel on November 14, 2011.
- On November 16, 2011, David B. Roberts, President, will provide
an update on the Company at 3:30pm at the Lazard Capital Markets
8th Annual Healthcare Conference at the Pierre Hotel in New York
City.
- On December 6, 2011, J.J. Pellegrino, Chief Financial
Officer, will provide an update on the Company at 11:20am at
the Canaccord Genuity 6th Annual Cardiovascular, Aesthetics &
Metabolic Disorders Conference at the St. Regis Hotel in San
Francisco, CA.
- On December 8, 2011, the Company will present at the SMID-West
Investor Conference 2011 in Chicago, IL.
About LeMaitre Vascular
LeMaitre Vascular is a provider of devices for the treatment of
peripheral vascular disease, a condition that affects more than 20
million people worldwide. The Company develops, manufactures
and markets disposable and implantable vascular devices to address
the needs of its core customer, the vascular surgeon.
Well-known to vascular surgeons, the Company's diversified
product portfolio consists of brand name devices used in arteries
and veins outside of the heart, including the Expandable LeMaitre
Valvulotome and the Pruitt F3 Carotid Shunt.
LeMaitre and the LeMaitre Vascular logo are registered
trademarks of LeMaitre Vascular, Inc. This press release
contains other trademarks and trade names of the Company.
For more information about the Company, please visit
http://www.lemaitre.com. The LeMaitre Vascular, Inc. logo is
available at
http://www.globenewswire.com/newsroom/prs/?pkgid=10015
CONTACT: J.J. Pellegrino
Chief Financial Officer
LeMaitre Vascular, Inc.
781-425-1691
jpellegrino@lemaitre.com
LeMaitre Vascular (NASDAQ:LMAT)
Historical Stock Chart
From Apr 2024 to May 2024
LeMaitre Vascular (NASDAQ:LMAT)
Historical Stock Chart
From May 2023 to May 2024